896 / 1544
Summarising
•
Models to convert dose distributions into clinical outcome
exist and have been verified in certain cases (e.g. rectum,
lung, liver)
•
Care must taken if extending the application outside the
range where the parameter-fitting has been done
•
If possible, take into account the weight of the clinical
variables (including the genetic ones) in the models
•
(Iso-NTCP treatment plan individualisation could be a strategy to improve
clinical outcome
•
Inclusion of deformation during the treatment (doses really absorbed in
the voxels, elastic match, shrinkage effects etc))